CompletedInterventionalPhase 3Updated Nov 25, 2025
Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis | NCT02778919 | Trialant
CompletedInterventionalPhase 2Updated Jun 4, 2019
Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis
ClinicalTrials.gov ID
NCT02778919
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Last Update Posted
Jun 4, 2019Actual
Start Date
May 9, 2016Actual
Primary Completion Date
Mar 23, 2018Actual
Completion Date
Mar 23, 2018Actual
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship of KLH-2109 compared to placebo in Japanese patients with endometriosis.
Endometriosis
KLH-2109
Placebo
Leuprorelin acetate
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female patients with endometriosis
Exclusion Criteria:
Patients with clinically significant hepatic, renal, or cardiovascular dysfunction